Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Abyssinia Biosciences is a preclinical-stage biotechnology company focused on developing next-generation antibody therapeutics for oncology and infectious diseases. The company utilizes a proprietary masking technology platform designed to create "pro-antibodies" that remain inactive in systemic circulation and are selectively activated within the tumor microenvironment. This approach aims to enhance the safety and efficacy of potent targets, such as CD47, by minimizing off-target toxicities. Headquartered in Rockville, Maryland, Abyssinia Biosciences is advancing a pipeline of monoclonal and bispecific antibodies to address high unmet medical needs in cancer immunotherapy and viral infections.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Abyssinia Biosciences.